MKI67 and breast cancer: In total, 14.0% and 3.5% of BC cases (n = 87 and n = 22) showed moderately and severely impaired EPR (group III and IV, median baseline Ki67 25.0% and 42.5%, median post‐pET Ki67 20.0% and 42.5%, respectively) (Figure S1).